Bioscience trendsAug 23, 2026

How GLP-1 receptor drugs may change immune and metabolism functions in people with HIV

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Aug 24, 2026

Abstract

HIV-specific trials demonstrate reductions in visceral adiposity, body weight, inflammatory biomarkers, and liver fat.

Antiretroviral therapy (ART) has led to increased prevalence of weight gain, adipose dysfunction, and inflammation among aging people with HIV.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 RAs may offer transformative benefits for managing these issues.
Exploratory studies suggest GLP-1 RAs could influence gut health, immune cell movement, and markers of aging, but these findings are preliminary.
Challenges related to lean-mass loss, weight regain after stopping treatment, and access to drugs are important considerations.
Current evidence positions GLP-1 RAs as promising but unproven components of cardiometabolic care for people with HIV.

Simplified

Antiretroviral therapy (ART) has transformed HIV infection into a manageable chronic condition, but pathological weight gain, adipose dysfunction, and persistent inflammation are increasingly prevalent among aging people with HIV (PWH). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 RAs have emerged as transformative therapies, although PWH were underrepresented in pivotal trials. This review integrates randomized trials, observational cohorts, pharmacogenomic studies, and emerging mechanistic evidence within a framework of GLP-1-mediated immunometabolic reprogramming. HIV-specific trials demonstrate reductions in visceral adiposity, body weight, inflammatory biomarkers, and liver fat. Exploratory or preliminary studies suggest possible effects on gut epithelial integrity, immune-cell trafficking, lymphoid pyroptosis, and DNA-methylation aging measures; however, several of these findings remain conference-level, preprint, or post hoc evidence and require prospective validation. We also examine lean-mass loss, weight regain after discontinuation, pharmacogenomic variation, drug access, and research priorities. Overall, GLP-1 RAs are promising components of cardiometabolic care for PWH, but immunologic, gerotherapeutic, and HIV-reservoir applications should currently be considered hypothesis-generating.

Full Text

Full text is available at the source.

View Full Text ↗

How GLP-1 receptor drugs may change immune and metabolism functions in people with HIV

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief